CMS Closes Tardive Dyskinesia Screening Gap for Medicare Plans

Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawFor the first time in any Medicare quality program, the Centers for Medicare & Medicaid Services (CMS) is formally encouraging clinicians to screen Medicare patients on antipsychotics for tardive dyskinesia (TD), a condition that affects an estimated 20% to 30% of long-term antipsychotic users but remains substantially underdiagnosed in routine practice (J Clin Psychiatry 2017;78[3]:e264-e278).The change i